Inhibition of Murine Breast Cancer Metastases by Hydrophilic AsS Nanoparticles Is Associated With Decreased ROS and HIF-1α Downregulation

Overview

Journal Front Oncol

Specialty Oncology

Date 2019 May 21

PMID 31106156

Citations 11

Authors

Tao Wang

Jie Meng

Chuan Wang

Tao Wen

Mengfan Jia

Yangyang Ge

Lifei Xie

Suisui Hao

Jian Liu

Haiyan Xu

Affiliations

Soon will be listed here.

Abstract

Arsenic sulfide (AsS) is a mineral drug that can be administrated orally and has been applied in the treatment of myeloid leukemia. The aim of this work is to investigate the therapeutic effect of AsS in highly metastatic triple-negative breast cancer (TNBC) animal model, as AsS has not been applied in the treatment of breast cancer yet. To overcome the poor solubility of original AsS, a formulation of hydrophilic AsS nanoparticles (e-AsS) developed previously was applied to mouse breast cancer cells as well as the tumor-bearing mice. It was shown that e-AsS was much more cytotoxic than r-AsS, strongly inhibiting the proliferation of the cells and scavenging intracellular reactive oxygen species (ROS). The oral administration of e-AsS significantly increased the accumulation of arsenic in the tumor tissue and eliminated ROS in tumor tissues. Besides, e-AsS could also inhibit the activation of hypoxia-inducible factor-1α (HIF-1α) and NLRP3 inflammasomes. Consequently, the angiogenesis was reduced, the metastasis to lung and liver was inhibited and the survival of tumor-bearing mice was prolonged. In conclusion, e-AsS holds great potential for an alternative therapeutics in the treatment of breast cancer, due to its unique function of correcting the aggressive microenvironment.

Citing Articles

Arsenic Nanoparticles Trigger Apoptosis via Induction in OECM-1 Cells.

Covarrubias A, Reyna-Jeldes M, Pedroso-Santana S, Marin S, Madero-Mendoza C, Demergasso C Int J Mol Sci. 2024; 25(12).

PMID: 38928430 PMC: 11204275. DOI: 10.3390/ijms25126723.

Hypoxia-inducible factor in breast cancer: role and target for breast cancer treatment.

Zhi S, Chen C, Huang H, Zhang Z, Zeng F, Zhang S Front Immunol. 2024; 15:1370800.

PMID: 38799423 PMC: 11116789. DOI: 10.3389/fimmu.2024.1370800.

Exploring novel strategies to improve anti-tumour efficiency: The potential for targeting reactive oxygen species.

Chasara R, Ajayi T, Leshilo D, Poka M, Witika B Heliyon. 2023; 9(9):e19896.

PMID: 37809420 PMC: 10559285. DOI: 10.1016/j.heliyon.2023.e19896.

Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens.

Srivastava N, Usmani S, Subbarayan R, Saini R, Pandey P Front Oncol. 2023; 13:1199105.

PMID: 37492478 PMC: 10363988. DOI: 10.3389/fonc.2023.1199105.

Possible therapeutic targets for NLRP3 inflammasome-induced breast cancer.

Wang X, Lin J, Wang Z, Li Z, Wang M Discov Oncol. 2023; 14(1):93.

PMID: 37300757 PMC: 10257378. DOI: 10.1007/s12672-023-00701-7.

References

Iommarini L, Porcelli A, Gasparre G, Kurelac I . Non-Canonical Mechanisms Regulating Hypoxia-Inducible Factor 1 Alpha in Cancer. Front Oncol. 2017; 7:286. PMC: 5711814. DOI: 10.3389/fonc.2017.00286. View

Ponde N, Zardavas D, Piccart M . Progress in adjuvant systemic therapy for breast cancer. Nat Rev Clin Oncol. 2018; 16(1):27-44. DOI: 10.1038/s41571-018-0089-9. View

Ma Q, Wang C, Li X, Guo H, Meng J, Liu J . Fabrication of water-soluble polymer-encapsulated As4S4 to increase oral bioavailability and chemotherapeutic efficacy in AML mice. Sci Rep. 2016; 6:29348. PMC: 4935940. DOI: 10.1038/srep29348. View

Palazon A, Tyrakis P, Macias D, Velica P, Rundqvist H, Fitzpatrick S . An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression. Cancer Cell. 2017; 32(5):669-683.e5. PMC: 5691891. DOI: 10.1016/j.ccell.2017.10.003. View

Sabharwal S, Schumacker P . Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel?. Nat Rev Cancer. 2014; 14(11):709-21. PMC: 4657553. DOI: 10.1038/nrc3803. View

Zhang H, Zhang Y, Chen C, Zhu X, Zhang C, Xia Y . A double-negative feedback loop between DEAD-box protein DDX21 and Snail regulates epithelial-mesenchymal transition and metastasis in breast cancer. Cancer Lett. 2018; 437:67-78. DOI: 10.1016/j.canlet.2018.08.021. View

Nogueira V, Hay N . Molecular pathways: reactive oxygen species homeostasis in cancer cells and implications for cancer therapy. Clin Cancer Res. 2013; 19(16):4309-14. PMC: 3933310. DOI: 10.1158/1078-0432.CCR-12-1424. View

Semenza G . The hypoxic tumor microenvironment: A driving force for breast cancer progression. Biochim Biophys Acta. 2015; 1863(3):382-391. PMC: 4678039. DOI: 10.1016/j.bbamcr.2015.05.036. View

Tao K, Fang M, Alroy J, Sahagian G . Imagable 4T1 model for the study of late stage breast cancer. BMC Cancer. 2008; 8:228. PMC: 2529338. DOI: 10.1186/1471-2407-8-228. View

10.

Cholujova D, Bujnakova Z, Dutkova E, Hideshima T, Groen R, Mitsiades C . Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma. Br J Haematol. 2017; 179(5):756-771. PMC: 5705577. DOI: 10.1111/bjh.14974. View

11.

Diana A, Franzese E, Centonze S, Carlino F, Della Corte C, Ventriglia J . Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs. Curr Oncol Rep. 2018; 20(10):76. DOI: 10.1007/s11912-018-0726-6. View

12.

Tomao F, Papa A, Zaccarelli E, Rossi L, Caruso D, Minozzi M . Triple-negative breast cancer: new perspectives for targeted therapies. Onco Targets Ther. 2015; 8:177-93. PMC: 4303459. DOI: 10.2147/OTT.S67673. View

13.

Movafagh S, Crook S, Vo K . Regulation of hypoxia-inducible factor-1a by reactive oxygen species: new developments in an old debate. J Cell Biochem. 2014; 116(5):696-703. DOI: 10.1002/jcb.25074. View

14.

Montagner M, Enzo E, Forcato M, Zanconato F, Parenti A, Rampazzo E . SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature. 2012; 487(7407):380-4. DOI: 10.1038/nature11207. View

15.

Chandel N, Maltepe E, GOLDWASSER E, Mathieu C, Simon M, Schumacker P . Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci U S A. 1998; 95(20):11715-20. PMC: 21706. DOI: 10.1073/pnas.95.20.11715. View

16.

Lu D, Qiu J, Jiang B, Wang Q, Liu K, Liu Y . Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood. 2002; 99(9):3136-43. DOI: 10.1182/blood.v99.9.3136. View

17.

Elias A . Triple-negative breast cancer: a short review. Am J Clin Oncol. 2009; 33(6):637-45. DOI: 10.1097/COC.0b013e3181b8afcf. View

18.

Wan L, Pantel K, Kang Y . Tumor metastasis: moving new biological insights into the clinic. Nat Med. 2013; 19(11):1450-64. DOI: 10.1038/nm.3391. View

19.

Schroder K, Tschopp J . The inflammasomes. Cell. 2010; 140(6):821-32. DOI: 10.1016/j.cell.2010.01.040. View

20.

Rankin E, Giaccia A . Hypoxic control of metastasis. Science. 2016; 352(6282):175-80. PMC: 4898055. DOI: 10.1126/science.aaf4405. View